Publication date: Dec 13, 2024
This study aimed to evaluate the diagnostic value of rapid simultaneous RNA amplification and testing for tuberculosis (SAT-TB) in smear-negative pulmonary tuberculosis (PTB). We performed a multicenter prospective analysis of 206 patients with smear-negative suspected PTB between December 2018 and March 2022. We collected sputum or bronchoalveolar lavage fluid (BALF) for simultaneous SAT-TB and Xpert Mycobacterium tuberculosis/rifampin (MTB/RIF) assays. The efficiency of SAT-TB detection was also evaluated. The final analysis included 161 patients with smear-negative suspected PTB, of whom 114 provided sputum specimens and 47 provided BALF specimens. In sputum samples, the area under the curve, sensitivity, and specificity of SAT-TB for diagnosing PTB were 0. 75, 50. 7%, and 100. 0%, respectively, and those of the Xpert MTB/RIF assay were 0. 81, 62. 3%, and 100. 0%, respectively. The kappa coefficient k of the consistency between SAT-TB and Xpert MTB/RIF in sputum specimens was 0. 686. In BALF specimens, the area under the curve, sensitivity, and specificity of SAT-TB for diagnosing PTB were 0. 79, 57. 1%, and 100. 0%, respectively, and those of Xpert MTB/RIF were 0. 86, 76. 2%, and 96. 2%, respectively. The kappa coefficient k of the consistency between SAT-TB and Xpert MTB/RIF in BALF specimens was 0. 656. The SAT-TB and Xpert MTB/RIF assays were highly consistent in diagnosing smear-negative PTB. It is a valuable method for early detection, prevention, and managing smear-negative PTB suspects. Meanwhile, the detection efficiency and cost-effectiveness of SAT-TB are more suitable for the rapid diagnosis of smear-negative PTB in low- and middle-income countries.
Open Access PDF
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | pulmonary tuberculosis |
disease | MESH | tuberculosis |
pathway | KEGG | Tuberculosis |
drug | DRUGBANK | Rifampicin |
disease | IDO | assay |
disease | IDO | nucleic acid |